



Technical Memorandum

To: Physicians, Clinical Staff and Clients

From: Wesley J. Kim, M.D. Ana Ortega-Lopez, M.D. Amy Powers, MD
DLS Medical Director Lab Director Lab Director

Date: September 29, 2025

Subject: Transition to New von Willebrand, Factor Assays and Introduction of von Willebrand Activity Assay

1. Transition to New vWF Antigen and Factor Assays– Effective September 29, 2025

Starting September 29, 2025, Diagnostic Laboratory Services (DLS) will upgrade its coagulation testing platform from Stago to Werfen. This transition is designed to improve the accuracy of test results and reduce turnaround times, ultimately enhancing patient care.

Below are the revised reference ranges that will be implemented with the new system:

Test Report Name	Reference range			
	Current Range (Stago)	Reporting unit	New Range (Werfen)	Reporting unit
von Willebrand Antigen	50-160	%	42.0-176.3	%
Factor VIII	50-200	%	50-150	%
Factor IX	50-200	%	65-150	%
Factor VIII Inhibitor (Bethesda)	<0.3	BU	<0.6	BU

2. Launch of von Willebrand Factor Activity Assay

DLS is introducing a fully automated von Willebrand Factor (vWF) activity assay using glycoprotein Ib-binding (GPIbR) technology. This method replaces traditional platelet-based ristocetin cofactor (vWF:RCO) assays with latex beads coated in recombinant GPIb. The new assay will provide more precise and efficient diagnosis and monitoring of von Willebrand Disease (VWD).

3. Discontinuation of Factor IX Inhibitor Assay

Due to low testing volume, the Factor IX Inhibitor assay will be discontinued and transitioned to a send-out test.

For further information, please contact Client Services at 808-589-5101.

“Great Science – Great People”

Diagnostic Laboratory Services, Inc., 99-859 Iwaiwa St., Aiea, HI 96701